Improved clinical parameters of Tau.P301L mice vaccinated with ACI-35. Clara Theunis Natalia Crespo-Biel Valérie Gafner Maria Pihlgren María Pilar López-Deber Pedro Reis David T. Hickman Oskar Adolfsson Nathalie Chuard Dorin Mlaki Ndao Peter Borghgraef Herman Devijver Fred Van Leuven Andrea Pfeifer Andreas Muhs 10.1371/journal.pone.0072301.g004 https://plos.figshare.com/articles/figure/_Improved_clinical_parameters_of_Tau_P301L_mice_vaccinated_with_ACI_35_/776851 <p>(A) The left panel shows the evolution of the bodyweight of Tau.P301L mice over 3 months of ACI-35 vaccination relative to PBS injected Tau.P301L mice. The panel on the right presents the loss in bodyweight of the Tau.P301L mice at day 91 relative to the start of the study (day -7). Data: mean± SEM (p = 0.094, unpaired Student's t-test). (B) Clasping score of vaccinated Tau.P301L mice compared to placebo injected Tau.P301L mice. (C) Rotarod performance of ACI-35 vaccinated Tau.P301L mice compared to PBS-injected Tau.P301L mice, tested over 300 sec on the accelerating rod (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072301#s2" target="_blank">Methods</a> section for details). Data: mean± SEM. (E) Mortality of Tau.P301L mice vaccinated with ACI-35 versus placebo Tau.P301L mice.</p> 2013-08-19 05:08:48 immunology immunity immunizations immunotherapy Model organisms Animal models mouse Clinical immunology vaccination vaccines Vaccine development Clinical research design Preclinical models neurology dementia Alzheimer disease Neurodegenerative diseases mice vaccinated